Emcure Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE168P01015
  • NSEID: EMCURE
  • BSEID: 544210
INR
2,336.05
-9.85 (-0.42%)
BSENSE

Nov 20

BSE+NSE Vol: 86.47 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ajanta Pharma
Acutaas Chemical
Gland Pharma
Emcure Pharma
Ipca Labs
Sai Life
Piramal Pharma
Anthem Bioscienc
Glaxosmi. Pharma
Wockhardt
Abbott India
Why is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 22.52%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.74 times
3
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 22.52%
4
Positive results in Sep 26
  • ROCE(HY) Highest at 23.46%
  • NET SALES(Q) Highest at Rs 2,820.47 cr
  • PBDIT(Q) Highest at Rs 587.83 cr.
5
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 04-Nov-26 and has generated 7.43% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, DOW and OBV
6
Majority shareholders : Promoters
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Emcure Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Emcure Pharma for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Emcure Pharma
71.27%
2.06
34.68%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
18.76%
EBIT Growth (5y)
31.82%
EBIT to Interest (avg)
8.24
Debt to EBITDA (avg)
0.99
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
1.37
Tax Ratio
26.88%
Dividend Payout Ratio
8.34%
Pledged Shares
0.04%
Institutional Holding
13.43%
ROCE (avg)
20.87%
ROE (avg)
18.90%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
40
Industry P/E
40
Price to Book Value
8.30
EV to EBIT
27.66
EV to EBITDA
21.97
EV to Capital Employed
6.58
EV to Sales
4.49
PEG Ratio
1.03
Dividend Yield
0.15%
ROCE (Latest)
23.79%
ROE (Latest)
20.85%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company
ROCE(HY)

Highest at 23.46%

NET SALES(Q)

Highest at Rs 2,820.47 cr

PBDIT(Q)

Highest at Rs 587.83 cr.

PBT LESS OI(Q)

Highest at Rs 442.60 cr.

PAT(Q)

Highest at Rs 325.57 cr.

EPS(Q)

Highest at Rs 17.16

-3What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 147.34 cr

Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Net Sales - Quarterly
Highest at Rs 2,820.47 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 587.83 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 442.60 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 442.60 cr has Grown at 25.9% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 351.69 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 325.57 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 325.57 cr has Grown at 26.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 258.04 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 17.16
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Emcure Pharma
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 147.34 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents